TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02690571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bronchoscopy
Description: The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
Study: NCT02248597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study: NCT03432897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill
Description: 300 mg BID
Study: NCT00834080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
Study: NCT03432897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: 22-42 days post Olaparib patients will undergo surgery
Study: NCT01058278

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Selective Laser trabeculoplasty
Description: The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser trabeculoplasty
Description: The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser trabeculoplasty
Description: The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
Study: NCT03718845

Intervention type: BEHAVIORAL
Intervention: Mind-Body Medicine Curriculum
Description: The Mind-Body Medicine curriculum consists of presentations on different mind-body techniques as well as the research supporting the use of these techniques.The mind-body technique is then practiced in a supportive small group setting. Mind-body techniques will include guided imagery, relaxation techniques, several forms of meditation, autogenic training and biofeedback.
Study: NCT01295060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: 84 mg Octreotide Implant
Study: NCT03047265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
Study: NCT04835246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra IMDx system
Description: The Spectra IMDx system is intended to be used in conjunction with conventional white light endoscopy in upper gastrointestinal endoscopic procedure to identify patients with high risk of developing and/or having gastric cancer and it is intended for use on patients above and equal to the age of 18.
Study: NCT03749395

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
Study: NCT04948008

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI306
Description: IBI306 is a kind of Proprotein convertase subtilisin/kexin 9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI306
Description: IBI306 is a kind of Proprotein convertase subtilisin/kexin 9
Study: NCT03183128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SER-109
Description: SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors~Other Names:~Eubacterial Spores, Purified Suspension, Encapsulated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).
Study: NCT00266058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine
Description: participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
Study: NCT04217564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: Nutritional counselling based on the nutritional assessment will be conducted. A booklet that contains the whole instructions and dietary records will be provided to help remembering information and record their application of the plan.
Study: NCT04747015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
Study: NCT03361683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Description: Randomized patients will receive oxygen through a high nasal flow device capable of delivering humidified, heated air at an output rate of 40 L/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask
Description: Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
Study: NCT01821976

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ertl Procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burgess Procedure
Study: NCT00637702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Description: single dose and multiple dose, escalating
Study: NCT03571880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex-assisted isometric strength testing
Description: The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodex-assisted isometric strength testing
Description: The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
Study: NCT02589223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory Stimulation
Description: Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
Study: NCT00554281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of glucose sensor (Paradigm Guardian)
Description: Use glucose sensor to prevent episodes of severe hypoglycemia
Study: NCT04747015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical traction
Description: sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus. Meanwhile (CCT ) is avoided and watchful waiting for signs of placental separartion till 90 seconds end
Study: NCT00760110

Intervention type: DEVICE
Intervention: blood pressure measurements based on HBP or CBP
Description: To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
Study: NCT03850197

Intervention type: DEVICE
Intervention: EarPopper
Description: The EarPopper is 510(K) regulated (510(K) Number K073401) and is marketed as a safe and effective way to aid muscle-assisted ET opening. It is a Politzer device, and aids ET opening by blowing a constant stream of air into the nasal cavity. It consists of a single nose piece connected to an air pump with no adjustable pressure settings. During the study, the subject will be asked to place the nose piece into one of the nostrils while occluding the contralateral. The subject will then perform the maneuvers (swallow, Fish, blowing out into the EMST-150).

Intervention type: DEVICE
Intervention: EarPopper
Description: The EarPopper is 510(K) regulated (510(K) Number K073401) and is marketed as a safe and effective way to aid muscle-assisted ET opening. It is a Politzer device, and aids ET opening by blowing a constant stream of air into the nasal cavity. It consists of a single nose piece connected to an air pump with no adjustable pressure settings. During the study, the subject will be asked to place the nose piece into one of the nostrils while occluding the contralateral. The subject will then perform the maneuvers (swallow, Fish, blowing out into the EMST-150).

Intervention type: DEVICE
Intervention: Tympanometry
Description: The Tympanometer is 510(K) regulated (510(K) Number K083861) and is marketed as a way to measure auditory impedance and acoustics reflex by producing controlled levels of test tones and signals. It will be used before and after each maneuver for both the EarPopper and Tubomanometry tests to assess middle ear pressure change.

Intervention type: DEVICE
Intervention: Tympanometry
Description: The Tympanometer is 510(K) regulated (510(K) Number K083861) and is marketed as a way to measure auditory impedance and acoustics reflex by producing controlled levels of test tones and signals. It will be used before and after each maneuver for both the EarPopper and Tubomanometry tests to assess middle ear pressure change.

Intervention type: DEVICE
Intervention: Tubomanometry
Description: Tubomanometry is an established test of Eustachian tube function. It is an easily-administered test used in clinical laboratories. It consists of a nosepiece and an ear canal pressure probe coupled to a manometer and air pump. When the nosepiece and ear canal probe is in place, a maneuver, such as swallowing, will cause the tubomanometer to generate a bolus of air at 30, 40, or 50 mbar through the nosepiece. In the event that the Eustachian tube opens, the tympanic membrane will be displaced, which in turn will be sensed by the ear probe. This event will be recorded as a Eustachian tube opening. For this test, the investigators will ask the subject to perform the maneuvers (swallow, Fish, blowing out into the EMST-150).
Study: NCT03850197

Intervention type: DEVICE
Intervention: Tubomanometry
Description: Tubomanometry is an established test of Eustachian tube function. It is an easily-administered test used in clinical laboratories. It consists of a nosepiece and an ear canal pressure probe coupled to a manometer and air pump. When the nosepiece and ear canal probe is in place, a maneuver, such as swallowing, will cause the tubomanometer to generate a bolus of air at 30, 40, or 50 mbar through the nosepiece. In the event that the Eustachian tube opens, the tympanic membrane will be displaced, which in turn will be sensed by the ear probe. This event will be recorded as a Eustachian tube opening. For this test, the investigators will ask the subject to perform the maneuvers (swallow, Fish, blowing out into the EMST-150).
Study: NCT01488786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainPort Vision Device
Description: 2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
Study: NCT02373098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: 66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
Study: NCT02704182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
Study: NCT01974141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Gel
Description: Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapsone Gel Vehicle
Description: Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Study: NCT03681444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular diet
Description: Patients will be provided with any type of food preferred at any time in any quantity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clear fluid diet
Description: Patients will be provided with~* Plain water~* Fruit juices without pulp, such as grape juice, filtered apple juice, and cranberry juice~* Soup broth (bouillon or consommé)~* Clear sodas, such as ginger ale and Sprite~* Gelatin (Jell-O)~* Tea or coffee with no cream or milk added~* Sports drinks that don't have color

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low residue diet
Description: The Low Residue Diet is the same as the soft diet with the added limitation of milk to one pint. It provides foods that are easily digestible. It is often used as a transition diet from liquids to the general diet. Indigestible fiber is reduced by using tender cooked vegetables and ripe, canned or cooked fruits from which the tough skins and seeds have been removed. Tender meat or meat made tender in the cooking process is used, thus reducing the amount of connective tissue.~Adequacy: By following the recommended guidelines, the diet will be adequate according to the Recommended Daily Allowance.~Note: For patients with dentures this diet can be modified by the substitution of ground meat for whole meat and excluding all raw vegetables. Personal tolerances determine food choices; avoid foods that cause GI (gastrointestinal) distress prior to the admission even though that food may be on the foods included list.
Study: NCT01988974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert for Atrial Fibrillation Program
Description: Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Sleep
Description: Participants will receive a 45 minute face to face instruction about sleep hygiene
Study: NCT03681444

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
Study: NCT05904444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microperimetric biofeedback training
Description: Microperimetry biofeedback training is a noninvasive stragegy to develop a new trained retinal locus or strength the spontaneous preferred retinal locus to get better visual performances.The rationale of MBFT consists in reeducating visual system to a new visual condition, promoting retina-brain transmission, and further enhancing synaptic plasticity and neural capacity by acoustic biofeedback or structured light stimulus biofeedback.
Study: NCT00473486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed, carboplatin, sorafenib
Description: Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed, carboplatin, placebo
Description: Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
Study: NCT03382509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BI 1467335
Description: Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Twice Daily
Study: NCT03143803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyherbal capsule coccinia, bougainvillea, catharanthus
Description: A unique combination of 3 herbs that lower blood sugars

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar looking inactive powder
Study: NCT05206448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: Clomiphene Citrate tablet
Study: NCT00603135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first-line i/v-levetiracetam
Description: No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
Study: NCT01348802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push + Pull
Description: Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pull
Description: Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
Study: NCT02557061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal surgery (resection)
Description: Colorectal surgery (resection) is done for patient with colorectal cancer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Pre-operative blood sampling is done for patient with colorectal cancer
Study: NCT01986556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 1)
Study: NCT02500004

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET-MRI-imaging
Description: BAT activity: 18F-FDG PET-MRI-imaging.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET-MRI-imaging
Description: BAT activity: 18F-FDG PET-MRI-imaging.
Study: NCT02874586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma exchange combination of immunosuppressive regimens